To determine whether elevated levels of hemostatic and inflammatory markers [von Willebrand factor (vWF), fibrinogen, D-dimer, factor VII, factor VIII, PAI-1, tPA, beta-thromboglobulin (␤-TG), CRP, and WBC count] are associated with increased peripheral arterial disease (PAD) prevalence, measured by low ABI, we studied 13,778 participants from the ARIC study in a cross-sectional analysis after adjustment for major cardiovascular risk factors. PAD was positively associated with fibrinogen, vWF, factor VIII, WBC count, D-dimer, ␤-TG, and CRP (p for trend Ͻ0.05) but not with the other markers. Adjusted odds ratios for the highest versus the lowest quartile of fibrinogen in men and women, respectively, were 3.49 (95% CI 1.68-7.26) and 2.44 (95% CI 1.58-3.77); for vWF 2.36 (95% CI 1.36-4.07) and 1.45 (95% CI 1.00-2.10); for factor VIII 2.31 (95% CI 1.36-3.94) and 1.68 (95% CI 1.14-2.48). In a smaller subset, the sex and risk factor adjusted odds ratio for the highest versus the lowest quartile of D-dimer was 2.70 (95% CI 1.56-4.65), for ␤-TG was 1.80 (95% CI 1.12-2.88), and for CRP was 1.57 (95% CI 0.84-2.95). Plasma levels of hemostatic and inflammatory markers are elevated in PAD, suggesting these processes are involved in the pathophysiology of PAD.
Introduction
Stenosis of the lower extremity arteries by atherosclerosis, or peripheral arterial disease (PAD), is an important public health problem. [1] [2] [3] [4] [5] [6] This disorder is easily diagnosed by a measurement of a decreased ankle-brachial index (ABI). PAD not only causes significant reductions in quality of life through impairment of ambulatory function, it is also associated with a significantly elevated mortality rate due to an increased rate of cardiovascular ischemic events, primarily myocardial infarction and stroke. [7] [8] [9] PAD serves as a marker of chronic, systemic endothelial damage. Rupture or erosion of a lower limb arterial atherosclerotic plaque leads to exposure of tissue factor, underlying intima, phospholipids, and other thrombogenic proteins; this leads to activation of the coagulation system and potential formation of an occlusive or non-occlusive thrombus over the disrupted plaque.
Previous epidemiologic investigations have demonstrated that elevations of plasma hemostatic markers (e.g. von Willebrand factor (vWF), fibrinogen, D-dimer, and factor VIII) predict a greater incidence or recurrence of coronary ischemic events or ischemic stroke. [10] [11] [12] [13] [14] [15] [16] Elevations of these hemostatic factors may reflect the presence of atherosclerotic lesions and associated inflammatory and procoagulatory activity. One study found that individuals with unstable angina had the greatest elevations in these markers, those with stable angina had lesser elevations, and those with asymptomatic CHD had the lowest marker levels. 17 A small number of epidemiologic studies have evaluated the role that these hemostatic markers might play in the pathophysiology of PAD. [18] [19] [20] [21] [22] [23] These studies, along with a series of clinical studies, [24] [25] [26] [27] [28] [29] suggest an association between PAD and some hemostatic or inflammatory markers, particularly fibrinogen, D-dimer, and C-reactive protein (CRP). However, the roles of vWF, factor VIII, factor VII, tissue plasminogen activator (tPA), plasminogen activator inhibitor (PAI-1), and ␤-thromboglobulin (␤-TG) are not yet clearly defined.
Because PAD, coronary heart disease (CHD), and cerebrovascular disease represent different clinical manifestations of the atherosclerotic process, it would be reasonable to assume that hemostatic and/or inflammatory markers would be associated with PAD and ischemic risk. We tested the hypothesis that plasma levels of pro-thrombotic and inflammatory markers are associated positively with PAD prevalence in a population-based, cross-sectional study.
Methods
The Atherosclerosis Risk in Communities (ARIC) study is a prospective, multi-center investigation of the natural history, etiology, and clinical manifestations of atherosclerotic disease in men and women of different racial backgrounds from four communities in the United States: Forsyth County, North Carolina; Jackson, Mississippi; the northwest suburbs of Minneapolis, Minnesota; and Washington County, Maryland. 30 The entire ARIC cohort consists of 15,792 individuals, aged 45-64 years, who were recruited between 1987 and 1989 for a baseline examination that included studies to detect the presence of atherosclerosis and evaluate atherosclerotic risk factors. Individuals underwent three subsequent triennial exams and continue to be followed for incident cardiovascular and cerebrovascular ischemic events. This analysis pertains only to cross-sectional baseline data.
At the baseline visit, the ABI was measured on resting participants using the Dinamap 1846 SX. Posterior tibial artery systolic pressures were measured twice, 5-8 minutes apart, in one randomly selected leg. Brachial artery systolic pressures were measured in the right arm every 5 minutes during a carotid ultrasound examination. The ABI was calculated by dividing the average of the two ankle pressure measurements by the average of the first two brachial pressure readings. 31, 32 The correlation between the duplicate blood pressure readings was 0.92 in the leg and 0.90 in the arm. The mean absolute difference between the duplicate readings was 0.5 mmHg (95% confidence interval (CI) 0.3-0.6) in the leg and 3.0 mmHg (95% CI 2.8-3.2) in the arm. Presence or absence of PAD was defined in the ARIC study as an ABI Ͻ 0.90. In supplemental analyses we used a lower ABI cutpoint for women (0.85) because the mean ABI is lower in women than men; 32,33 patterns of association for these analyses were similar to the primary analyses.
Information on smoking status (current, former, never) and amount (pack-years) was estimated from interview. Medication use was assessed by questionnaire. Body mass index (BMI, kg/m 2 ) was computed from height and weight. The ratio of waist (umbilical level) to hip (maximum buttocks) circumferences (waist-to-hip ratio) was calculated as a measure of fat distribution. To measure blood pressure, three measurements were taken with a random-zero sphygmomanometer. The mean of the last two measurements was used. Prevalent hypertension was defined by a screening visit systolic pressure Ն 140 mmHg, diastolic pressure Ն 90 mmHg, or self-reported use of antihypertensive medications. Diabetes was defined as a fasting plasma glucose level Ն 126 mg/dl, a nonfasting plasma glucose level Ն 200 mg/dl, selfreported physician diagnosis of diabetes, or pharmacologic treatment for diabetes.
Fasting blood was drawn from an antecubital vein, serum and plasma separated, and aliquots stored at -70°C for a few weeks until analysis. 34 Hemostatic markers measured in the entire ARIC sample at the baseline examination included fibrinogen, vWF, factor VII activity, and factor VIII activity. 14, 34 As reported previously, reliability coefficients (between person variance divided by total variance) obtained from repeated testing of individuals over several weeks were 0.72 for fibrinogen, 0.68 for vWF, 0.78 for factor VII, and 0.86 for factor VIII. 35 In addition, WBC, HDL cholesterol, total cholesterol, and triglycerides were measured at baseline and LDL cholesterol was calculated. 36 During 1997 to 1998, frozen plasma aliquots drawn at baseline (1987-89) were thawed for additional hemostatic and inflammatory marker assays -␤-TG, CRP, tPA antigen, D-dimer, and PAI-1 antigen -from participants with PAD as well as a stratified random sample of the entire ARIC cohort sampled with exclusion for cardiovascular disease and stratification by age, sex, and carotid intima-media thickness. D-dimer, tPA antigen, and PAI-1 antigen were measured by sandwich enzyme immunoassay. Plasma ␤-TG and CRP were determined by enzyme-linked immunoabsorbant assay. 34, 37 Reliability coefficients obtained from repeated testing of individuals were 0.73 for D-dimer, 0.81 for tPA, 0.72 for PAI-1, and 0.83 for ␤-TG. 38 The reliability coefficient for blinded duplicate tubes from a single blood draw was 0.96 for CRP. 39 Hemostasis laboratory personnel were blinded with regard to the case-control status of the samples.
Data analysis
From the ARIC cohort of 15,792 participants, we excluded those with missing data on prevalent CHD status (n ϭ 344) or stroke status (n ϭ 373); 43 because they were of a race other than black or white; 51 because there were few blacks from Minnesota or Washington County; 83 due to warfarin use; and 518 with missing ABI data. This left 14,380 individuals for analysis. Three groups were used in this analysis: PAD cases (n ϭ 441), non-cases (n ϭ 13,939), and the cohort random sample (n ϭ 907).
To compare the PAD cases, the full set of non-cases, and the cohort random sample, we computed the prevalence of PAD for categorical variables, and the 25th, 50th, and 75th percentiles for continuous variables at baseline. To assess the association between PAD prevalence and hemostatic factors, prevalence odds ratios (POR) of PAD (and 95% CIs) were calculated using logistic regression for quartiles of hemostatic factors, with the lowest quartile serving as the reference. Tests for trend of the odds ratios across quartiles were conducted by modeling a single continuous variable that assumed the value of the respective within-quartile median for all individuals in the prospective quartile. The analyses in the whole cohort for Table 1 and Figure 1 were run sex-specific. To control for confounding, models were adjusted for age, ethnicity/ race, history of cardiovascular disease, BMI, waistto-hip ratio, smoking status, pack-years of smoking, systolic blood pressure, antihypertensive use, diabetes, lipid medication use, HDL cholesterol, and LDL cholesterol. The logistic regression analyses using the cohort random sample for Figure 2 pooled men and women, adjusted for sex, and were weighted for strata sampling fractions by the use of the SUDAAN software procedure. Pooling was done because of the small sample size.
Results
The baseline age-adjusted characteristics of PAD cases (median ABI ϭ 0.84), the non-case comparison group, and the cohort random sample (median ABI ϭ 1.15 and 1.15, respectively) are given in Table 1 . Compared with the full group without PAD, participants with PAD had a greater prevalence of traditional atherosclerotic risk factors (tobacco use, diabetes, elevated systolic blood pressure and cholesterol). Median levels were greater in PAD cases than the rest of the cohort for fibrinogen (329 versus 293 mg/dl), vWF (125 versus 109%), factor VIII (137 versus 126%), and WBC count (6700 versus 5800 cells/ml). The factors measured in only PAD cases and the cohort random sample (␤-TG, CRP, tPA antigen, D-dimer, and PAI-1 antigen) were all higher in PAD cases. Figure 1 presents sex-specific, adjusted, prevalence odds ratios for PAD by quartiles of hemostatic and inflammatory markers that were measured in the entire ARIC cohort. In both men and women the prevalence of PAD was higher in the upper three quartiles compared with the lowest quartile of fibrinogen (fourth . WBC showed a weak positive association, and factor VII did not show any significant association, with PAD prevalence. Men and women were pooled for the remaining analyses due to a smaller sample size. Among markers measured only in PAD cases and the cohort random sample (Figure 2 ), D-dimer showed the strongest association with PAD (fourth versus first quartile: POR ϭ 2.70 [95% CI 1.56-4.65]), with the odds ratios of PAD prevalence increasing linearly across D-dimer quartiles (p-value for trend ϭ 0.001). There were also significant linear trends (p Ͻ 0.05) for PAD in relation to ␤-TG and CRP, with the POR for the fourth versus first quartile being 1.80 (95% CI 1.12-2.88) for ␤-TG and 1.57 (95% CI 0.84-2.95) for CRP. Adjustment for platelet count had a negligible effect on prevalence odds ratios for ␤-TG. tPA antigen and PAI-1 antigen were not related to PAD prevalence. To investigate whether these associations were different in men and women, analyses were stratified by sex, and tests for interaction by sex were computed. A difference was observed only for ␤-TG interaction (interaction p ϭ 0.01), with the association between PAD and ␤-TG being totally absent in women but strongly positive in men (PORs ϭ 1.0, 1.17, 1.80, 7.81, p Ͻ 0.001 across quartiles in men).
To address whether the combination of elevated fibrinogen and elevated D-dimer confers a greater risk of PAD than elevation of one marker alone, fibrinogen and D-dimer were dichotomized at the 50th percentile and participants were categorized into four groups: (1) low fibrinogen/low D-dimer (n ϭ 250), (2) low fibrinogen/high D-dimer (n ϭ 135), (3) high fibrinogen/low D-dimer (n ϭ 121), and (4) high fibrinogen/high D-dimer (n ϭ 189). Adjusted odds ratios were calculated for each group with the low fibrinogen/low D-dimer participants as the reference. High levels of both D-dimer and fibrinogen above the 50th percentile suggest very high risk of PAD (POR ϭ 2.72 [95% CI 1.66-4.46]). For low fibrinogen/high D-dimer the POR ϭ 1.25 (95% CI 0.65-2.40), and for high fibrinogen/low D-dimer the POR ϭ 1.38 (95% CI ϭ 0.79-2.43).
Discussion
In this population-based sample, individuals with PAD demonstrated greater plasma levels of several inflammatory and hemostatic markers compared with those free of PAD. Specifically, higher levels of fibrinogen, vWF, factor VIII, WBC, D-dimer, ␤-TG, and CRP were associated with greater PAD prevalence. The remaining markers -factor VII, TPA antigen, PAI-1 antigen -showed no association with PAD prevalence.
Fibrinogen, which increases in response to inflammation promoting platelet aggregation and fibrin clot deposition, 16 also has been shown to be elevated in individuals who are at risk for, or who have, CHD and cerebrovascular disease. [10] [11] [12] [13] [14] We found fibrinogen strongly associated with PAD in both men and women, and it appeared to display a dose-response pattern. This is consistent with findings from the Edinburgh Artery Study, 18, 20 which showed an independent, positive, cross-sectional association between elevated fibrinogen and PAD (defined by ABI or claudication). Other studies consistently demonstrated positive cross-sectional or longitudinal associations between PAD and fibrinogen. 19, [21] [22] [23] [24] 26 D-dimer is a byproduct of cross-linked fibrin degradation by plasmin and therefore a marker of thrombin production and fibrinolytic activity. Several studies have reported that greater prevalence or worsening of PAD is associated with increased D-dimer. 20, 21, 26, 28, 29, 40 Our data corroborate a strong association between elevated D-dimer levels and prevalent PAD and suggest that thrombus formation occurs at sites of plaque in the peripheral arteries and may be a component in the natural history of PAD. Further evidence for a role of thrombosis in PAD are the increased levels of ␤-TG (a marker of platelet activation), vWF (a marker of endothelial damage), and coagulation factor VIII (which is bound to VWF) in individuals with PAD. vWF is produced by megakaryocytes, platelets and the endothelium, and mediates platelet aggregation and adhesion. 41 Blann et al. also found a positive relation between PAD and vWF, 25 but Allison et al. found PAD not associated with vWF or factor VIII. 21 PAI-1 is a major inhibitor of fibrinolysis by deactivation of tPA. The lack of association in our study is also consistent with previous investigations. Both PAI-1 and tPA are strongly correlated with most conventional atherosclerotic risk factors (especially BMI and smoking), so that the weak associations found in some studies were eliminated after the risk factors were adjusted for. 15 A previous ARIC investigation found PAI-1 to be associated with CHD in a univariate analysis, but not after adjustment for other atherosclerotic risk factors. 15 The lack of association between factor VII and PAD in Adjusted a odds ratios (and 95% confidence intervals) of peripheral artery disease by quartile of hemostatic and inflammation markers. a Adjusted for age, sex, race, field center, smoking status and pack-years, BMI, waist-to-hip ratio, SBP, use of antihypertensives, diabetes, use of lipid medication, and LDL and HDL cholesterol. Excludes those with prevalent CHD or stroke at baseline. Peripheral artery disease defined as ankle-brachial index Յ 0.90. P-value for test of trend across quartiles (see 'Methods').
this analysis was also consistent with cross-sectional results from both ADMIT and the Cardiovascular Health Study. 19, 24 CRP is an acute phase reactant produced by hepatocytes after induction by IL-6, IL-1, or TNF-␣ in the setting of acute inflammation. 42, 43 We observed a modest positive association between levels of CRP and PAD, consistent with somewhat stronger associations in most previous prospective and cross-sectional investigations. 21, 22, [26] [27] [28] [29] 44 In addition, the WBC count was associated positively with PAD prevalence, further implicating inflammation in the pathophysiology of PAD.
A possibility for no association between PAD and some hypothesized markers is that ABI was measured using an oscillatory method in only one leg. Assessing one leg only would have decreased the sensitivity, but increased the specificity for detecting PAD. However, because there were many individuals without PAD in this study, erroneously labeling some who actually had PAD as disease-free would only negligibly attenuate the PORs between PAD and plasma markers. In addition, we had only single measures of the plasma markers, and error in their measurement could also attenuate the PORs. Finally, the small sample sizes resulting from the selective measurement of ␤-TG, CRP, tPA, PAI-1, and D-dimer in a small subset of the cohort may have compromised our ability to detect weak associations of tPA and PAI-1 with PAD.
Because of this study's cross-sectional design, any inferences regarding cause and effect from these observed associations cannot be made. It is not known whether elevation of any of these inflammatory or hemostatic factors acts in the initiation of the atherosclerotic disease process, or whether these plasma marker elevations are a result of the atherosclerotic process. It has been proposed that a combination of these pathways is at work. 45 Further prospective studies of incident claudication or decreasing ABI while following marker levels over time would provide additional insight into the temporal association between PAD and these variables, contribute information regarding their pathophysiologic relation, and provide a direction for future therapies.
However, despite the lack of temporal data this analysis contributes information about the pathophysiology of PAD. These results reaffirm strong prothrombotic and inflammatory components to the pathophysiology of PAD. It is possible that the symptoms and progression of PAD are not due solely to stenotic leg arteries by atherosclerotic plaque build up. They may also result from repeated formation of thrombi at or near plaque sites that contribute to decreased blood flow in the leg resulting in muscle ischemia, claudication, endothelial damage, inflammation, and further progression of disease.
